Zhimeng Biopharma
EN
|
简体
Home
About Us
People
Leadership Team
Scientific Advisors
Pipeline
News
Investors
Join Us
Contact
News
Mar 05, 2020
Zhimeng Biopharma Announces the First-in-Human Dosing in Phase I Clinical Trial of ZM-H1505R Designed for the Treatment of Chronic Hepatitis B Virus Infection
Jan 19, 2020
Zhimeng Biopharma Received Approval from US FDA for Starting Clinical Trial on Its HBV Capsid Inhibitor ZM-H1505R
Nov 13, 2019
Zhimeng Biopharma Announced Completion of Series Pre-A Financing Led by Lake Capital and Shenzhen Capital Group Co., Ltd.
Feb 21, 2019
Zhimeng Biopharma announces that it will present new anti-HBV data on its novel hepatitis B virus (HBV) nucleocapsid formation inhibitor CB-001 at the EASL-AASLD Joint Meeting on HBV Endpoints in London, March 8-9, 2019
Nov 09, 2018
Zhimeng Biopharma presented the discovery and efficacy data of its novel hepatitis B virus (HBV) nucleocapsid formation inhibitor CB-001 at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco
prev
1
2
next
Get in touch
Contact Us
About Us
Leadership Team
Scientific Advisors